Literature DB >> 30266667

Jejunal absorption of aprepitant from nanosuspensions: Role of particle size, prandial state and mucus layer.

C Roos1, D Dahlgren1, E Sjögren1, M Sjöblom2, M Hedeland3, H Lennernäs4.   

Abstract

The number of highly lipophilic active pharmaceutical ingredients (APIs) in pharmaceutical development has been constantly increasing over recent decades. These APIs often have inherent issues with solubility and dissolution, limiting their oral bioavailability. Traditionally, a reduction in particle size to the micrometer range has been used to improve dissolution. More recently, size reduction to the nanometer range has been introduced, which further increases the dissolution rate, but may also involve other mechanisms for increasing bioavailability. The effect of particle size on the absorption of aprepitant was investigated using the single-pass intestinal perfusion (SPIP) model in the rat jejunum. Phosphate buffer, fasted-state simulated intestinal fluid (FaSSIF), and fed-state simulated intestinal fluid (FeSSIF) were used as perfusion media to increase understanding of the processes involved and the effects of colloidal structures. The role of mucus on intestinal absorption was investigated by adding the mucolytic agent N-acetyl-cysteine (NAC). The absorption of aprepitant from the nanosuspensions was similar with all perfusion media (buffer = FaSSIF = FeSSIF), whereas food had a pronounced effect on absorption from the microsuspensions (FeSSIF > FaSSIF > buffer). The colloidal structures hence contributed to absorption from the microsuspensions. Partitioning of aprepitant from the nanosuspension into the colloidal structures decreased the amount of nanoparticles available, which offset the effect of food. The appearance flux of aprepitant in blood was non-significantly decreased for nanosuspensions of aprepitant with NAC versus without NAC in buffer (ratio of 2:1), indicating that particle deposition in the mucus may have been decreased as the layer thinned, with subsequently reduced intestinal absorption. The study also showed that the SPIP model is suitable for investigating detailed absorption mechanisms using complex perfusion media, which increase the biorelevance of the model.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30266667     DOI: 10.1016/j.ejpb.2018.09.022

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  4 in total

Review 1.  Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models.

Authors:  David Dahlgren; Erik Sjögren; Hans Lennernäs
Journal:  ADMET DMPK       Date:  2020-09-17

2.  Non-Effective Improvement of Absorption for Some Nanoparticle Formulations Explained by Permeability under Non-Sink Conditions.

Authors:  Kazuya Sugita; Noriyuki Takata; Etsuo Yonemochi
Journal:  Pharmaceutics       Date:  2022-04-07       Impact factor: 6.525

3.  Enabling formulations of aprepitant: in vitro and in vivo comparison of nanocrystalline, amorphous and deep eutectic solvent based formulations.

Authors:  Henrik Palmelund; Jonas B Eriksen; Annette Bauer-Brandl; Jukka Rantanen; Korbinian Löbmann
Journal:  Int J Pharm X       Date:  2021-06-05

Review 4.  Progress in the development of stabilization strategies for nanocrystal preparations.

Authors:  Jingru Li; Zengming Wang; Hui Zhang; Jing Gao; Aiping Zheng
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.